The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

CMAJ

Volumn 190, Issue 22, 2018, Pages E677-E687

  Shah, Hemant ^a   Bilodeau, Marc ^b   Burak, Kelly W ^c   Cooper, Curtis ^d   Klein, Marina ^e   Ramji, Alnoor ^f   Smyth, Dan ^g   Feld, Jordan J ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; GLECAPREVIR PLUS PIBRENTASVIR; HOLKIRA PAK; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; SOFOSBUVIR PLUS VELPATASVIR PLUS VOXILAPREVIR; ANTIVIRUS AGENT; VIRUS ANTIBODY;

ARTICLE; CANADA; CHRONIC HEPATITIS C; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; END STAGE LIVER DISEASE; FOLLOW UP; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICAL ASSESSMENT; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PUBLIC HEALTH; DISEASE MANAGEMENT; FEMALE; GENOTYPE; HEALTH CARE SURVEY; HEPACIVIRUS; LIVER; PATHOGENICITY; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATION; VIROLOGY;

ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CANADA; DISEASE MANAGEMENT; FEMALE; GENOTYPE; HEALTH CARE SURVEYS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 85048208204     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.170453     Document Type: Article

References (94)

1. Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol 2008;22:381-7.
2. Myers RP, Krajden M, Bilodeau M, et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol 2014;28:243-50.
3. Schanzer DL, Paquette D, Lix LM. Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis. CMAJ Open 2014;2:E139-44.
4. Rotermann M, Langlois K, Andonov A, et al. Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Health Rep 2013;24:3-13.
5. Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015;61:41-5.
6. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821-9.
7. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139:1593-601.
8. Myers RP, Cooper C, Sherman M, et al. Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol 2011;25:503-10.
9. Neary MP, Cort S, Bayliss MS, et al. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999;19(Suppl 1):77-85.
10. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa- 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
11. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-7.
12. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
13. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
14. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-516. e1.
15. Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8(3):280-288, 288.e1.
16. Myers RP, Shah H, Burak KW, et al. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29:19-34.
17. Hull MSS, Shafran S, Wong A, et al. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 updated Canadian HIV/hepatitis C adult guidelines for management and treatment. Can J Infect Dis Med Microbiol 2016;2016:4385643. doi:10.1155/2016/4385643.
18. Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003;139:493-8.
19. Methodology Manual and Policies from the ACCF/AHA Task Force on Practice Guidelines [report]. American College of Cardiology Foundation and American Heart Association; 2010. Available: http://my.americanheart.org/idc/ groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm-319826 .pdf (accessed 2017 Oct. 17).
20. Myers RP, Ramji A, Bilodeau M, et al. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-75.
21. Mathiesen UL, Franzen LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002;34:516-22.
22. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferaseto- platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726-36.
23. Trubnikov M, Yan P, Archibald C. Estimated prevalence of hepatitis C virus infection in Canada, 2011. Can Commun Dis Rep 2014;40:429-36.
24. Ha S, Totten S, Pogany L, et al. Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016;42:57-62.
25. Wong WW, Tu HA, Feld JJ, et al. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-21.
26. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013;62:362-5.
27. Granados-Garcia V, Contreras AM, Garcia-Pena C, et al. Cost-effectiveness analysis of different testing strategies that use antibody levels to detect chronic hepatitis C in blood donors. PLoS One 2016;11:e0154625.
28. Bulteel N, Partha Sarathy P, Forrest E, et al. Factors associated with spontaneous clearance of chronic hepatitis C virus infection. J Hepatol 2016;65:266-72.
29. Janjua NZ, Kuo M, Yu A, et al. The population level cascade of care for hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBio- Medicine 2016;12:189-95.
30. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011;364:2199-207.
31. Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med 2017;167:311-8.
32. Backus LI, Belperio PS, Shahoumian TA, et al. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology 2018 Jan. 29 [Epub ahead of print] doi: 10.1002/hep.29811.
33. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
34. Emery JS, Kuczynski M, La D, et al. Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol 2017;112:1298-308.
35. Hellard M, Rolls DA, Sacks-Davis R, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 2014;60:1861-70.
36. Murphy G, Farah B, Wong W, et al. 2014. Direct-acting antiviral agents for chronic hepatitis C genotype 1 [report]. Ottawa: Canadian Agency for Drugs and Technologies in Health; Oct. 3, 2014.
37. Barua S, Greenwald R, Grebely J, et al. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the united states. Ann Intern Med 2015;163:215-23.
38. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liverrelated mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011;53:150-7.
39. Innes HA, McDonald SA, Dillon JF, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and causespecific outcomes. Hepatology 2015;62:355-64.
40. Marshall AD, Saeed S, Barrett L, et al. Restrictions for reimbursement of directacting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 2016;4:E605-14.
41. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
42. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599-607.
43. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-17.
44. Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018;16:417-26.
45. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis ( EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-8.
46. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018;378:354-69.
47. Reddy KR, Lim JK, Kuo A, et al. All-oral direct-acting antiviral therapy in HCVadvanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther 2017;45:115-26.
48. Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
49. Guha IN, Myers RP, Patel K, et al. Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology 2011;54:1454-62.
50. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferaseto- platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007;46:912-21.
51. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8.
52. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134:960-74.
53. Myers RP, Elkashab M, Ma M, et al. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol 2010;24:661-70.
54. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;55:199-208.
55. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009;16:300-14.
56. Kelly ML, Riordan SM, Bopage R, et al. Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: a multi-centre observational study. PLoS One 2018;13:e0192763.
57. Kronenberger B, Zeuzem S. New developments in HCV therapy. J Viral Hepat 2012;19(Suppl 1):48-51.
58. Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, et al. Efficacy of second generation direct-acting antiviral agents for treatment naive hepatitis C genotype 1: a systematic review and network meta-analysis. PLoS One 2015;10:e0145953.
59. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
60. Chaudhary R, Tepper M, Eisaadany S, et al. Distribution of hepatitis C virus genotypes in Canada: results from the LCDC Sentinel Health Unit Surveillance System. Can J Infect Dis 1999;10:53-6.
61. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1087-97.
62. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
63. Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US veterans with HCV. Hepatology 2014;60:98-105.
64. Chen T, Terrault N. Treatment of chronic hepatitis C in patients with cirrhosis. Curr Opin Gastroenterol 2016;32:143-51.
65. Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 2016;64:234-8.
66. Maan R, van Tilborg M, Deterding K, et al. Safety and effectiveness of directacting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol 2016;14:1821-30.e6.
67. Fernandez-Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis c virus in patients with advanced cirrhosis: Always justified? Analysis of the HEPA-C registry [abstract GS01]. Proceedings of the 51st Annual Meeting of the European Association for the Study of the Liver (EASL); 2016 Apr. 13-17; Barcelona, Spain.
68. Coilly A, Pageaux G-P, Houssel-Debry P, et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA? [abstract 95]. Proceedings of the 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2015 Nov. 13-17. San Francisco.
69. Belli L, Berenguer M, Rockenschaub S-R, et al. Impact of direct anti-viral agents on inactivation/de-listing of liver transplant candidates listed for decompensated c cirrhosis: a European study (PS036). Proceedings of the 51st Annual Meeting of the European Association for the Study of the Liver (EASL); 2016 Apr. 13-17; Barcelona, Spain.
70. Pascasio J, Vinaixa C, Ferrer M, et al. Interferon (INF)-free antiviral therapy in cirrhotic patients infected with hepatitis c on the waiting list for liver transplantation. efficacy and impact on delisting and liver function [abstract FRI- 464]. Proceedings of the 51st Annual Meeting of the European Association for the Study of the Liver (EASL); 2016 Apr. 13-17; Barcelona, Spain.
71. Islam N, Krajden M, Shoveller J, et al. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. Lancet Gastroenterol Hepatol 2017;2:200-10.
72. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139:1593-601.
73. Sarrazin C, Isakov V, Svarovskaia ES, et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvirbased therapies. Clin Infect Dis 2017;64:44-52.
74. Martin NK, Vickerman P, Dore GJ, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol 2016;65:17-25.
75. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
76. Janjua NZ, Chong M, Kuo M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol 2017;66:504-13.
77. El-Serag HB, Kanwal F, Richardson P, et al. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology 2016;64:130-7.
78. D'Ambrosio R, Aghemo A, Rumi MG, et al. Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. Liver Int 2018 Jan. 27 [Epub ahead of print].
79. D'Ambrosio R, Degasperi E, Aghemo A, et al. Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon. PLoS One 2016;11:e0155967.
80. Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
81. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
82. Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017;376:2134-46.
83. Poordad F, Pol S, Asatryan A, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 2018;67:1253-60.
84. Wong WW, Lee KM, Singh S, et al. Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open 2017;5:E97-108.
85. Wong WWL, Erman A, Feld JJ, et al. Model-based projection of health and economic effects of screening for hepatitis C in Canada. CMAJ Open 2017;5:E662-72.
86. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C. J Hepatol 2015;63:199-236.
87. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-54.
88. Grad R, Thombs BD, Tonelli M, et al.; Canadian Task Force on Preventive Health Care. Recommendations on hepatitis C screening for adults. CMAJ 2017;189:E594-604.
89. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945- 1965. MMWR Recomm Rep 2012;61(RR-4):1-32.
90. Bottero J, Brouard C, Roudot-Thoraval F, et al. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. Liver Int 2016;36:1442-9.
91. Bolotin S, Feld JJ, Garber G, et al. Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. PLoS One 2018;13:e0191184.
92. Payne E, Totten S, Archibald C. Hepatitis C surveillance in Canada. Can Commun Dis Rep 2014;40:421-8.
93. Garber G, Bolotin S. PHO Grand Rounds: Population-based estimate of hepatitis C virus prevalence in Ontario, Canada [Webinar]. Toronto: Public Health Ontario; 2016 Nov. 29.
94. Combating hepatitis B and C to reach elimination by 2030. Geneva: World Health Organization; May 2016. Available: http://apps.who.int/iris/bitstream/ handle/10665/206453/WHO-HIV-2016.04-eng.pdf;jsessionid=B665CA5BAF2F6 8F5A06EA95AA5EDCFDC?sequence=1 (accessed Oct. 17, 2017).